Diabetes & Endocrine System

FORSEE

This is a multi-center, open-label, single-arm study. All subjects will be pediatric patients with central precocious puberty judged to be candidates for GnRH (gonadotropin releasing hormone) analog therapy, and all will receive two injections of FP-001 42 mg six-month apart in an unblinded fashion.

Primary disease category:

Diabetes & Endocrine System

Secondary disease category(ies):

Children, Infants & Newborns

Pathway to Prevention

TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes.

Primary disease category:

Diabetes & Endocrine System

Secondary disease category(ies):

Children, Infants & Newborns